Cargando…

Initial outcomes of mitomycin intravascular chemoembolization (MICE) for corneal neovascularization

PURPOSE: To report on the preliminary outcomes of mitomycin C (MMC) intravascular chemoembolization (MICE) for corneal neovascularization (NV). METHODS: This is a retrospective case series of three consecutive eyes that underwent MICE for progressive corneal NV with sight threatening lipid keratopat...

Descripción completa

Detalles Bibliográficos
Autores principales: Mimouni, Michael, Ouano, Dean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801928/
https://www.ncbi.nlm.nih.gov/pubmed/35099664
http://dx.doi.org/10.1007/s10792-022-02240-6
_version_ 1784642565085069312
author Mimouni, Michael
Ouano, Dean
author_facet Mimouni, Michael
Ouano, Dean
author_sort Mimouni, Michael
collection PubMed
description PURPOSE: To report on the preliminary outcomes of mitomycin C (MMC) intravascular chemoembolization (MICE) for corneal neovascularization (NV). METHODS: This is a retrospective case series of three consecutive eyes that underwent MICE for progressive corneal NV with sight threatening lipid keratopathy. A 1.0 cc syringe was partially filled with MMC (0.4 mg/mL) and attached to a 33-gauge needle used to cannulate the vessels. The MMC (0.01–0.05 ml) was injected with enough retrograde hydrostatic force to fill efferent and afferent vessels. Follow-up ranged from 4 months to 1 year. RESULTS: Three eyes of three patients aged 59, 73 and 33 years were included. There were no intraoperative or postoperative complications associated with the MICE procedure. Patient 1 presented with progressive corneal NV and lipid keratopathy secondary to herpes zoster ophthalmicus (HZO) and a best-corrected spectacle visual acuity (BSCVA) of 20/100 Snellen. At one-year post-MICE, there was no recurrence (BSCVA was 20/20 Snellen). Patient 2 presented with idiopathic lipid keratopathy (BSCVA 20/50 Snellen). At four months post-MICE, there were no signs of recurrence (BSCVA 20/20 Snellen). Patient 3 presented with corneal NV and lipid keratopathy secondary to HZO (BSCVA 20/30 Snellen). At four months following two MICE treatments, resolution of the lipid keratopathy was noted (BSCVA 20/20 Snellen). CONCLUSIONS: Preliminary findings suggest that MICE may be an additional modality for treating progressive corneal NV with lipid keratopathy. Larger comparative studies with longer follow-up are warranted. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10792-022-02240-6.
format Online
Article
Text
id pubmed-8801928
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-88019282022-01-31 Initial outcomes of mitomycin intravascular chemoembolization (MICE) for corneal neovascularization Mimouni, Michael Ouano, Dean Int Ophthalmol Original Paper PURPOSE: To report on the preliminary outcomes of mitomycin C (MMC) intravascular chemoembolization (MICE) for corneal neovascularization (NV). METHODS: This is a retrospective case series of three consecutive eyes that underwent MICE for progressive corneal NV with sight threatening lipid keratopathy. A 1.0 cc syringe was partially filled with MMC (0.4 mg/mL) and attached to a 33-gauge needle used to cannulate the vessels. The MMC (0.01–0.05 ml) was injected with enough retrograde hydrostatic force to fill efferent and afferent vessels. Follow-up ranged from 4 months to 1 year. RESULTS: Three eyes of three patients aged 59, 73 and 33 years were included. There were no intraoperative or postoperative complications associated with the MICE procedure. Patient 1 presented with progressive corneal NV and lipid keratopathy secondary to herpes zoster ophthalmicus (HZO) and a best-corrected spectacle visual acuity (BSCVA) of 20/100 Snellen. At one-year post-MICE, there was no recurrence (BSCVA was 20/20 Snellen). Patient 2 presented with idiopathic lipid keratopathy (BSCVA 20/50 Snellen). At four months post-MICE, there were no signs of recurrence (BSCVA 20/20 Snellen). Patient 3 presented with corneal NV and lipid keratopathy secondary to HZO (BSCVA 20/30 Snellen). At four months following two MICE treatments, resolution of the lipid keratopathy was noted (BSCVA 20/20 Snellen). CONCLUSIONS: Preliminary findings suggest that MICE may be an additional modality for treating progressive corneal NV with lipid keratopathy. Larger comparative studies with longer follow-up are warranted. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10792-022-02240-6. Springer Netherlands 2022-01-31 2022 /pmc/articles/PMC8801928/ /pubmed/35099664 http://dx.doi.org/10.1007/s10792-022-02240-6 Text en © The Author(s), under exclusive licence to Springer Nature B.V. 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Paper
Mimouni, Michael
Ouano, Dean
Initial outcomes of mitomycin intravascular chemoembolization (MICE) for corneal neovascularization
title Initial outcomes of mitomycin intravascular chemoembolization (MICE) for corneal neovascularization
title_full Initial outcomes of mitomycin intravascular chemoembolization (MICE) for corneal neovascularization
title_fullStr Initial outcomes of mitomycin intravascular chemoembolization (MICE) for corneal neovascularization
title_full_unstemmed Initial outcomes of mitomycin intravascular chemoembolization (MICE) for corneal neovascularization
title_short Initial outcomes of mitomycin intravascular chemoembolization (MICE) for corneal neovascularization
title_sort initial outcomes of mitomycin intravascular chemoembolization (mice) for corneal neovascularization
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801928/
https://www.ncbi.nlm.nih.gov/pubmed/35099664
http://dx.doi.org/10.1007/s10792-022-02240-6
work_keys_str_mv AT mimounimichael initialoutcomesofmitomycinintravascularchemoembolizationmiceforcornealneovascularization
AT ouanodean initialoutcomesofmitomycinintravascularchemoembolizationmiceforcornealneovascularization